FBXO9

Across TCGA pan-cancer cohorts, FBXO9 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of FBXO9’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where FBXO9 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types FBXO9 is over-expressed in tumor, although a few such as HNSC and LSCC show the opposite, repressed pattern.

HNSC, CCRCC, and LSCC are the cancer types where FBXO9 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FBXO9 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	All	−0.257	.006	7	view →
CCRCC	Female	All	+0.474	<.001	6	view →
LSCC	All	All	−0.120	.005	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

FBXO9–HNSC

Open the HNSC breakdown →